Regulatory agencies approve new Parkinson's and Rett syndrome treatments while reassessing safety profiles of existing drugs, with clinical trials validating Paxlovid dosing for children.

The EMA approved a new dual-release levodopa-carbidopa formulation designed to address motor fluctuations in moderate-to-severe Parkinson's disease patients, combining both immediate and sustained-release mechanisms.

Trofinetide received EMA marketing authorization for Rett syndrome after the agency reversed its previous decision, marking the first drug specifically approved to treat this rare neurological disorder.

The EMA revoked approval for Tavneos (avacopan) in treating active granulomatosis with polyangiitis after new data indicated the autoimmune disease drug's risks outweighed its benefits.

Europe initiated a regulatory review of Rifadin syrup (rifampicin), a tuberculosis medication, following carcinogen safety concerns raised by the Dutch medicines agency.

uniQure's gene therapy AMT-130 for Huntington's disease faces a regulatory pathway split, potentially seeking UK approval while negotiating with the FDA over requirements for a larger, sham-controlled trial.

Pfizer's post-marketing trial confirmed that Paxlovid achieves therapeutic blood concentrations in high-risk children aged 6 and older with mild-to-moderate COVID-19, supporting current dosing recommendations.

Home-based human papillomavirus screening for cervical cancer demonstrated modest uptake rates in a diverse community setting, raising questions about patient adoption of accessible screening methods.

Data from EULAR 2026 revealed that one-third of chronic rheumatic pain patients report severe, unresolved pain 15 years after diagnosis, indicating a significant treatment gap in current anti-inflammatory protocols.